Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis

BACKGROUND: Central nervous system lymphoma (CNSL) is an aggressive lymphoma. Studies investigating primary CNSL determined that the Bruton tyrosine kinase (BTK) played an important role in pathogenesis. Ibrutinib, an oral BTK inhibitor, is a new treatment strategy for CNSL. The purpose of this meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Liwei, Sun, Xuefei, Wu, Yuchen, Cui, Qu, Chen, Yuedan, Liu, Yuanbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280788/
https://www.ncbi.nlm.nih.gov/pubmed/34277452
http://dx.doi.org/10.3389/fonc.2021.707285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280788/
https://www.ncbi.nlm.nih.gov/pubmed/34277452
http://dx.doi.org/10.3389/fonc.2021.707285

Ejemplares similares